Hybrigenics hires head of corporate and business development

William Vickery joins firm from ExonHit

Hybrigenics, a French bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialised in protein interactions services, has appointed William Vickery to the newly created position of head of corporate and business development.

Vickery was for five years senior director of business development at ExonHit.

Prior to joining ExonHit Therapeutics in 2006 and since 2003, he was business development director of Roche Pharmaceuticals in the US, where he was responsible for out-licensing and divestiture of Roche-developed assets.

‘I am very excited about joining Hybrigenics and look forward to helping the company establish strong partnerships to develop breakthrough therapeutics to treat cancers and other diseases,’ said Vickery.

You may also like

Research & Development

Hybrigenics and Servier sign three-year research deal

Will study deubiquitinating enzymes (DUBs) applied to a number of therapeutic areas
Ingredients

Hybrigenics develops new oral formulations of inecalcitol

New capsules are more concentrated in inecalcitol and contain a fixed 2mg amount that will be more convenient, with a maximum of two small capsules to swallow, which also favours compliance
Ingredients

Hybrigenics improves inecalcitol synthesis

French firm makes patent application for high-yield inecalcitol production
Packaging

ProMach Pharma presents new equipment at Pack Expo Las Vegas

Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
Pharmaceutical

CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability

Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Pharmaceutical

Keystone Folding Box Co. unveils Key-Pak Plus

Designed to protect children and empower seniors, it achieves top U.S. safety ratings and meets global accessibility standards
Subscribe now